These findings suggest that a reduced HOXB9 expression was correlated with more malignant GC clinical features, which is similar to previous findings involving another GC series [19], although different from those of HOXB9 expression in lung and breast cancers [14–16]. This evidence concerns the gene HOXB9 and gastric cancer.